Ser835
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser835  -  LATS2 (human)

Site Information
GSHVRQDsMEPSDLW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 28706304

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 3 ) , mass spectrometry ( 2 ) , phospho-antibody ( 1 , 3 ) , western blotting ( 1 , 3 )
Disease tissue studied:
bone cancer ( 3 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , OSCC ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
Chk1 (human) ( 1 )
Putative in vivo kinases:
Chk1 (human) ( 3 )
Kinases, in vitro:
Chk1 (human) ( 3 ) , LATS2 (human) ( 3 )
Treatments:
UV ( 3 )

Downstream Regulation
Effects of modification on LATS2:
activity, induced ( 1 ) , enzymatic activity, induced ( 3 ) , phosphorylation ( 1 , 3 )
Effects of modification on biological processes:
apoptosis, induced ( 3 ) , signaling pathway regulation ( 1 )

References 

1

Nozaki M, et al. (2019) LATS1/2 kinases trigger self-renewal of cancer stem cells in aggressive oral cancer. Oncotarget 10, 1014-1030
30800215   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Suzuki H, et al. (2013) Lats2 phosphorylates p21/CDKN1A after UV irradiation and regulates apoptosis. J Cell Sci 126, 4358-68
23886938   Curated Info